Fig. 2.
Effect of disease status at the time of transplantation in children with de novo AMKL who do not have DS.
The 2-year survival estimate was 53% (95% CI = 11%-95%) for patients who were in CR at the time of HSCT and 0% for patients who had persistent disease at the time of HSCT (P = .028). HSCT indicates hematopoietic stem cell transplantation.